IsoRay, Inc. (ISR)
| Market Cap | 65.83M |
| Revenue (ttm) | 10.23M |
| Net Income (ttm) | -4.92M |
| Shares Out | 141.92M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 277,135 |
| Open | 0.462 |
| Previous Close | 0.464 |
| Day's Range | 0.460 - 0.477 |
| 52-Week Range | 0.400 - 2.810 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 1.63 (+251.4%) |
| Earnings Date | Nov 10, 2021 |
About ISR
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is ba...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for IsoRay stock is "Strong Buy." The 12-month stock price forecast is 1.63, which is an increase of 251.37% from the latest price.
News
Isoray Announces First Quarter Fiscal 2022 Financial Results
Prostate Revenue Increased Year-Over-Year for Second Consecutive Quarter Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year
Will IsoRay (ISR) Report Negative Earnings Next Week? What You Should Know
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Isoray To Announce First Quarter Fiscal 2022 Financial Results on November 10, 2021
Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT
American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray's Cesium-131
RICHLAND, Wash., Sept. 28, 2021 (GLOBE NEWSWIRE) -- The American Brachytherapy Society (ABS) has recognized Isoray's Cesium-131 in its recently released new consensus statement on the subject of low dos...
Recap: Isoray Q4 Earnings
Isoray(AMEX:ISR) stock fell by 3.68% on Wednesday after the company reported its Q4 earnings results on Tuesday, September 21, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Du...
Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT
IsoRay (ISR) Reports Q4 Loss, Tops Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 3.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2021 Financial Results
Record Full Year Revenue Fiscal Fourth Quarter Revenue Increased 19% Year-Over-Year
Will IsoRay (ISR) Report Negative Q4 Earnings? What You Should Know
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Isoray To Announce Fourth Quarter and Fiscal Year End 2021 Financial Results on September 21, 2021
Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT
IsoRay (ISR) Reports Q3 Loss, Tops Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 6.56%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Isoray Announces Third Quarter Fiscal 2021 Financial Results
Revenue Increased 10% Sequentially Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year
Isoray To Announce Third Quarter Fiscal 2021 Financial Results on May 13, 2021
Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT
Isoray Announces the Appointment of Donna Fort as Vice President Sales and Marketing
RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed V...
University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer ...
RICHLAND, Wash., March 31, 2021 (GLOBE NEWSWIRE) -- A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray's Cesi...
IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -0.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Isoray To Announce Second Quarter Fiscal 2021 Financial Results on February 9, 2021
Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT
IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Penny Stock Bubbles That Are About to Burst
There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.
Isoray to Present at the H.C. Wainwright BioConnect 2021 Conference
RICHLAND, Wash., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the b...
Why Change Healthcare, Isoray And Alkido Are Moving Today
Alkido Pharma (NASDAQ: AIKI) shares are trading higher after the company announced it executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. AIkido...
Isoray's Cesium-131 Spotlighted in Multiple Presentations at ASTRO
Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World's Premier Radiation Oncology Society Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Canc...
IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -21.32%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Isoray Announces First Quarter Fiscal 2021 Financial Results
Revenue Increased 3% Year-Over-Year
IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.